18-06-2026 02:00 via cell.com

Programmable mycolysins expand the antimicrobial toolkit against mycobacteria

In a timely advance for antimycobacterial biotechnology, Abouhmad et al. engineered modular ‘mycolysins’ that combine mycobacteriophage lysis functions with membrane-active peptides to efficiently breach the mycobacterial envelope and achieve pathogen intracellular killing. Their work opens a route that may accelerate the development of biologics against tuberculosis and nontuberculous mycobacterial diseases.
Read more »

Biotechnology news



The New Race to Find Treatments for Measles
With Measles Roaring Back, the Search for a Drug is On
Better Sex, Better Hair, Better Sleep: ‘Humanmaxxing’ Is Here
As Ebola Spreads in East Africa, Will China Step Up?
China’s Rise in Drug Development Looms Over U.S.
Reprogramming halophilic life for low-salt biomanufacturing
Biotechnologies based on the fungal bioluminescence pathway
Blue at the edge
The Rich and Powerful Want to Live Forever
Scientific breakthrough versus successful startup: teaching scientists to navigate bench to business
Engineered phage-derived lysins effectively kill mycobacterial pathogens
Clinical-scale bioreactor production of hiPSC-derived extracellular vesicles modulates miRNA and protein cargo to enhance angiogenic function
Synthetic M13 phage engagers expand CAR-T cell antigen recognition to overcome tumor heterogeneity
How to Turn a Chicken Egg Into a Drug Factory
Desktop versie